The Science Behind Test, Don't Guess

Baker et al. (Maturitas) established the foundational framework linking gut microbiota composition to oestrogen metabolism via β-glucuronidase secretion. The paper identifies how gut dysbiosis — characterised by lower microbial diversity — reduces deconjugation of oestrogens, lowering circulating oestrogen levels and contributing to obesity, metabolic syndrome, PCOS, cardiovascular disease, endometriosis, and cognitive decline. The bidirectional relationship — where low oestrogen also reshapes the microbiome — is described, creating a self-reinforcing cycle particularly relevant in perimenopausal women.

Hu et al. (Gut Microbes) provide a detailed mechanistic account of how gut microbial β-glucuronidase controls the enterohepatic circulation of oestrogen. Under normal conditions, this system maintains oestrogen homeostasis. When the homeostasis is broken — through dysbiosis, antibiotics, or gut inflammation — oestrogen metabolism is disturbed, with downstream effects across the endocrine system. The authors propose gut microbial β-glucuronidase as a potential early diagnostic biomarker for oestrogen-related disease.

Ervin et al. (Journal of Biological Chemistry) provide the first experimental demonstration that gut microbial β-glucuronidase enzymes from 35 different human gut bacteria can reactivate oestrogen glucuronides back into active oestrone and oestradiol. Different bacterial classes have different capacities for this reactivation, and the process can be selectively inhibited. This moved the estrobolome concept from theory to mechanism, with specific enzyme classes now identifiable as clinical targets.

Cross et al. (Gut Microbes) demonstrated that removal of ovarian hormones in mice — modelling menopause — directly altered the gut microbiome, increased gut permeability, elevated systemic inflammation, and transferred metabolic dysfunction to germ-free recipients via faecal transplant. The gut microbiome was shown to both respond to hormone changes and actively drive the metabolic deterioration associated with oestrogen loss.

Herman et al. (Comprehensive Physiology) provide the definitive review of HPA axis regulation — covering the neural pathways that drive CRH release, the glucocorticoid negative feedback mechanisms, and the multiple forms that chronic stress-induced HPA dysregulation can take: chronic basal hypersecretion, sensitised stress responses, and adrenal exhaustion. Crucially, the paper identifies that chronic stress responses can recruit entirely different neural circuits from acute responses — explaining why HPA dysregulation in long-term stressed clients looks nothing like the acute stress pattern.

Oyola & Handa (Stress) document the bidirectional relationship between the HPA axis and the HPG (sex hormone) axis — showing that gonadal steroids directly modulate HPA reactivity, and that HPA activation in turn suppresses sex hormone production. Oestradiol amplifies HPA stress responses in females, while testosterone in males is generally inhibitory. This bidirectionality explains why female clients with high stress load consistently show sex hormone suppression in their DUTCH results, and why addressing cortisol dysregulation is frequently a prerequisite to restoring hormonal balance.

Heck et al. (Neuropsychopharmacology) confirm that female HPA axis responses to stress are markedly greater than male responses — driven largely by oestradiol's facilitatory effect on HPA reactivity. The fluctuating oestrogen levels across the menstrual cycle create variable HPA reactivity throughout the month, contributing to the well-established female preponderance in stress-related disorders. The paper also identifies neuroactive steroid metabolites as a second layer of HPA modulation beyond the classical sex hormones.

Ring (American Journal of Medicine, 2025) reviews multifactorial contributors to HPA dysfunction — psychological stress, dietary imbalances, disrupted circadian rhythms, environmental toxins, gut health, and hormonal imbalances — and evaluates integrative treatment strategies including diurnal salivary cortisol profiling, mind-body therapies, dietary and lifestyle interventions, adaptogenic herbs, and targeted nutraceuticals. Notably published in a mainstream medical journal, this represents growing clinical acceptance of integrative approaches to HPA assessment and treatment.

Fluge et al. (JCI Insight) analysed 200 ME/CFS patients and 102 healthy controls, finding a specific reduction in amino acids that fuel oxidative metabolism via the Krebs cycle — primarily in female ME/CFS patients. The pattern strongly implicated functional impairment of pyruvate dehydrogenase (PDH), the enzyme that gates entry into aerobic energy production. Elevated PDH kinase expression was confirmed in peripheral blood cells. This study provided the first robust metabolic explanation for the post-exertional malaise that characterises ME/CFS — excessive lactate generation when oxidative phosphorylation is impaired.

Molnár et al. (GeroScience) synthesise the growing evidence that long COVID's characteristic symptoms — chronic fatigue, cognitive disturbance, and exercise intolerance — are substantially driven by mitochondrial dysfunction. SARS-CoV-2 impairs mitochondrial membrane potential, increases reactive oxygen species, disrupts mitophagy, and suppresses oxidative phosphorylation. The paper reviews therapeutic strategies targeting mitochondrial function including CoQ10, NAD+ precursors, and targeted dietary interventions, drawing parallels with ME/CFS and post-infectious fatigue syndromes more broadly.

Zong et al. (Signal Transduction and Targeted Therapy) provide a comprehensive review of mitochondrial dysfunction across cardiovascular disease, neurodegeneration, metabolic syndrome, and cancer — identifying convergent mechanisms: impaired oxidative phosphorylation, ROS overproduction, disrupted mitophagy, and mtDNA damage. Crucially for functional medicine application, the paper reviews dietary supplements — CoQ10, NAD+/NMN, targeted antioxidants — as mitochondria-targeted interventions with clinical translation potential.

Zhao et al. (Frontiers in Nutrition) conducted a sham-controlled randomised trial of IgG-based dietary elimination in 98 migraine patients. At 12 weeks, the true elimination group showed significantly greater reductions in migraine frequency, gastrointestinal symptoms, and sleep quality, alongside measurable reductions in inflammatory markers IL-6, TNF-α, and the neuropeptide CGRP. The mechanism proposed is that IgG-positive food consumption drives systemic chronic inflammation and sensitises trigeminal nerve endings — eliminated by removing the trigger foods.

Ostrowska et al. (Journal of Clinical Medicine) compared IgG-guided elimination-rotation diet against low-FODMAP diet and standard gastroenterologist dietary advice in 73 female IBS-M patients. The IgG-guided diet produced significantly greater reductions in abdominal pain, post-meal pain, and defecation-related pain than either comparator — with some symptoms resolving completely. The FODMAP diet improved bloating and mucus in stool. The control diet showed no significant improvements. The study directly pits IgG-guided intervention against the current gold-standard dietary approach in IBS and finds it superior.

Yang et al. (Frontiers in Immunology) followed 407 children with allergic diseases across respiratory, skin, and multi-system presentations. IgG4 positive rates exceeded 80% across all groups. After 3+ months of IgG4-guided dietary elimination, serum IgG4 levels decreased significantly alongside clinical symptom improvement. Crucially, the decline in IgG4 was identified as an independent predictor of symptom improvement (OR 1.41). The study also found no impact on IgE levels — confirming that IgG4 and IgE reactions are distinct immune pathways requiring separate clinical assessment.

Garmendia et al. (Immuno, 2025) present a balanced review of the food-specific IgG evidence — acknowledging both the clinical improvements seen with IgG-guided elimination diets in IBS, eosinophilic oesophagitis, IBD, and autoimmune conditions, and the legitimate concern that IgG antibodies can also reflect normal exposure rather than pathological reaction. The review concludes that IgG results should be interpreted within the clinical context of each patient rather than as standalone diagnostic markers — which is precisely how TDG integrates them alongside GI-MAP gut findings and symptom questionnaire data.

A consistent body of research demonstrates that iron deficiency symptoms — fatigue, cognitive impairment, hair loss, restless legs, and impaired thyroid hormone conversion — manifest at ferritin levels well within the conventional "normal" range. Studies in women of reproductive age have shown that ferritin below 50–70 µg/L is associated with significant symptom burden despite levels being above the conventional deficiency threshold of 10–12 µg/L. The conventional range was designed to identify frank anaemia, not to optimise iron-dependent metabolic processes. Thyroid T4-to-T3 conversion, a deiodinase-mediated process requiring adequate iron as a cofactor, is measurably impaired at ferritin levels that pass standard clinical review without comment.

Homocysteine is routinely included in comprehensive blood panels but rarely discussed in GP consultations when results fall below the conventional upper limit of 15 µmol/L. Yet prospective studies consistently demonstrate elevated cardiovascular risk, neurological vulnerability, and oestrogen detoxification impairment at homocysteine levels above 7–9 µmol/L — levels the conventional range treats as unremarkable. The functional optimal is below 7 µmol/L. A result of 11 µmol/L will not trigger a flag on a standard lab report. In functional medicine, it indicates methylation cycle impairment, likely B12 and folate insufficiency, and a modifiable cardiovascular risk factor.

The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) — calculated as fasting glucose (mmol/L) × fasting insulin (mIU/L) ÷ 22.5 — was validated as a surrogate measure of insulin resistance in 1985 and has since been confirmed across thousands of studies as a sensitive early marker. A HOMA-IR above 1.5 indicates early insulin resistance; above 2.0 indicates metabolic syndrome territory. Critically, HOMA-IR can be elevated when fasting glucose is 4.6–5.1 mmol/L — values the conventional range marks as entirely normal. Fasting insulin alone, without the HOMA-IR calculation, is rarely tested in NHS practice despite being the earliest available marker of the metabolic dysfunction that precedes cardiovascular disease, fatty liver, and type 2 diabetes by years.

The triglyceride-to-HDL ratio is one of the strongest predictors of small dense LDL particle predominance — the genuinely atherogenic form of LDL cholesterol that standard lipid testing does not distinguish from the large buoyant form. A TG:HDL ratio above 1.5 is associated with metabolic syndrome, insulin resistance, and a cardiovascular risk profile that total cholesterol dramatically underestimates. The Atherogenic Index of Plasma (AIP — log10 of TG:HDL) further refines this calculation. Neither appears on standard NHS lipid reports, which report total cholesterol, LDL, HDL, and triglycerides as separate values without calculating their relationships.

Cutshall, Bergstrom & Kalish (Complementary Therapies in Clinical Practice, 2016) evaluated a structured FDN-based programme in women presenting with fatigue, stress, and digestive complaints — the three symptom clusters most common in functional medicine practice. The protocol used salivary hormone testing, stool analysis, and targeted lifestyle intervention. Participants demonstrated statistically significant improvements across all three symptom domains. The study is notable for its use of the same biomarker-guided, multi-system assessment approach that underpins the TDG programme — and for demonstrating that outcomes improve when intervention follows testing rather than preceding it.

Coenzyme Q10 (ubiquinol) is essential for mitochondrial electron transport chain function — every cell that generates energy requires it. Statin medications inhibit the HMG-CoA reductase pathway used to synthesise CoQ10 endogenously, producing measurable depletion in long-term users. The clinical consequence — muscle pain, fatigue, and exercise intolerance — is well-documented and consistently underdiagnosed. CoQ10 supplementation at 100–200mg daily (as ubiquinol, the reduced form) is standard practice for any client on long-term statin therapy. The research base extends beyond statins to primary mitochondrial dysfunction, heart failure, Parkinson's disease, and ME/CFS.

Magnesium is a cofactor in over 300 enzymatic reactions and plays a direct regulatory role in HPA axis activity. Magnesium deficiency increases HPA reactivity — producing elevated cortisol — while cortisol itself drives urinary magnesium excretion, creating a self-reinforcing depletion cycle. Long-term PPI use, diuretic use, type 2 diabetes, and chronic psychological stress all deplete magnesium. RBC (red blood cell) magnesium is the functionally relevant measurement — serum magnesium is tightly regulated and remains normal until depletion is severe. Most clinical testing uses serum magnesium, which misses the majority of functional magnesium insufficiency.

Ferrous sulphate is the standard NHS iron supplement. It is also the form most associated with gastrointestinal side effects — constipation, nausea, and cramping — that reduce compliance. Iron bisglycinate chelate demonstrates equivalent or superior iron absorption at lower elemental doses with significantly fewer gastrointestinal effects, multiple comparative studies show. The chelated form is absorbed via a peptide transport mechanism that bypasses the standard non-haem iron absorption pathway, making it less susceptible to inhibition by phytates, tannins, and calcium. For clients with gut dysbiosis or compromised intestinal permeability, this distinction is clinically significant.

Lactoferrin is an iron-binding glycoprotein with a high affinity for free iron that modulates absorption, reduces oxidative iron toxicity, and has established antimicrobial and anti-inflammatory properties. For clients with recurrent or persistent iron deficiency where standard supplementation has failed — or where gut pathology is contributing to malabsorption — lactoferrin represents a clinical option supported by a growing body of evidence. It is particularly relevant in clients where elevated ferritin (as an acute-phase reactant) masks actual iron availability, and in post-infection recovery where gut barrier integrity is compromised.

Appropriately dosed exercise is one of the most potent non-pharmacological regulators of HPA axis reactivity. Regular moderate-intensity aerobic exercise reduces basal cortisol, improves the cortisol awakening response, enhances hypothalamic sensitivity to glucocorticoid negative feedback, and attenuates the cortisol response to psychological stressors. The dose-response relationship is non-linear — overtraining produces the opposite effect, driving HPA hyperactivity and cortisol excess that compounds the same dysregulation it was intended to address. This is why the TDG programme assesses exercise appropriateness — not just whether clients exercise, but whether the type, intensity, and volume of exercise is appropriate for their current HPA axis status.

Movement quality — defined as the ability to move through an appropriate range of motion with structural control — is a distinct clinical variable from exercise volume. Poor movement mechanics produce cumulative compensatory load on joint structures, contribute to chronic inflammatory states through repetitive micro-trauma, and accelerate functional decline with age. The physical attributes that underpin quality movement — stability, mobility, flexibility, strength, and power — all decline with age if not specifically trained. Power in particular, the capacity to produce force rapidly, declines fastest from the fifth decade and is the primary determinant of fall resistance and functional independence in older adults. The research on movement quality as a health variable is expanding rapidly as sports science and clinical medicine converge.

Schwaederle et al. (JAMA Oncology) meta-analysed 346 phase 1 clinical trials to compare outcomes between biomarker-guided and non-guided treatment arms. The biomarker-based approach was independently associated with a response rate of 30.6% versus 4.9% for non-personalised approaches — a six-fold difference. Progression-free survival was nearly doubled. Non-personalised targeted therapy performed no better than cytotoxic chemotherapy. The paper's conclusion is stark: applying targeted treatments without biomarker selection produces outcomes statistically equivalent to non-targeted approaches.